Printer Friendly

STERLING WINTHROP ANNOUNCES SANOFI WINTHROP LICENSING AGREEMENT FOR PREFILLED NEEDLE-FREE SYRINGE WITH BAXTER HEALTHCARE

 STERLING WINTHROP ANNOUNCES SANOFI WINTHROP LICENSING AGREEMENT
 FOR PREFILLED NEEDLE-FREE SYRINGE WITH BAXTER HEALTHCARE
 NEW YORK, Feb. 25 /PRNewswire/ -- Sterling Winthrop Inc. today announced that Sanofi Winthrop Pharmaceuticals has signed a licensing agreement with I.V. Systems Division of Baxter Healthcare Corporation under which Sanofi Winthrop will tip its Carpuject(R) line of prefilled syringes with Baxter's InterLink(TM) cannula, a blunt plastic component that replaces conventional sharp steel needles.
 Baxter introduced the InterLink System in 1989. Used by more than 900 hospitals, the InterLink System is the leading needle-free alternative to sharp steel needles. The system can replace more than two-thirds of the 6 billion needles used annually by U.S. hospitals for a variety of procedures including intravenous medication administration, blood sampling, drug vial access, and intravenous tubing connections. Use of the InterLink System reduces the risk of accidental needlesticks, the most common cause of disease transmission among healthcare workers.
 Sanofi Winthrop, one of the largest manufacturers of prefilled injectable medications, markets its unit-dose sterile cartridge under the Carpuject trademark, now celebrating its 20th anniversary on the market. Under the terms of the agreement, the Carpuject syringe will be modified for use with the InterLink Injection Port. The System will initially consist of I.V. lock maintenance products in 2 and 5 mL fill volumes.
 Kevin Swan, vice president of access systems, said, "Baxter is pleased to be associated with Sanofi Winthrop to expand the InterLink System technology. This alliance of leading healthcare companies is committed to providing products that create a safer work environment for hospital employees." Dan Peters, vice president, hospital products division, indicated, "Sanofi Winthrop has a long history of providing products which contribute to the efficiency and safety of injectable delivery systems. We see the partnership with Baxter and the InterLink System as an important step in fulfilling this ongoing commitment by expanding the availability of new and safer systems to the nursing and medical community."
 Concerns associated with AIDS, hepatitis B, and other bloodborne diseases offer a great challenge to manufacturers such as Sanofi Winthrop and Baxter Healthcare to take an innovative approach toward the development of new products. Every 30 seconds -- about a million times a year -- a U.S. doctor, nurse or other healthcare worker is stuck accidentally by a potentially contaminated needle. Up to 18,000 healthcare workers become infected with hepatitis annually. When exposed to infected blood through a needlestick injury, the chances are 10-35 percent of contracting the disease.
 Baxter Healthcare Corporation is the principal U.S. operating subsidiary of Baxter International Inc. (NYSE: BAX). Based in Deerfield, Ill., Baxter is the leading worldwide manufacturer and marketer of health-care products, systems and services. It offers more than 120,000 products to health-care providers in 100 countries. The company had 1991 revenues of $8.9 billion.
 Sanofi Winthrop Pharmaceuticals, which manufactures and markets pharmaceuticals in the United States, is the result of a global alliance between Sanofi and Sterling Winthrop Inc. Sterling Winthrop Inc., headquartered in New York, is a worldwide developer, manufacturer and marketer of pharmaceutical and consumer health products.
 -0- 2/25/92
 /CONTACT: Diane Iselin of Sterling Winthrop, 212-907-2341; or Cheri Moraca of Baxter Healthcare, 708-270-3768/
 (BAX) CO: Sterling Winthrop Inc.; Baxter Healthcare Corporation ST: New York, Illinois IN: HEA SU: LIC


GK-OS -- NY017 -- 2222 02/25/92 09:36 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 25, 1992
Words:555
Previous Article:IVAX ACQUIRES WILLEN DRUG COMPANY
Next Article:FIRST RUSSIAN FORD DEALERSHIP OPENS IN ST. PETERSBURG
Topics:


Related Articles
STERLING WINTHROP AND SANOFI ANNOUNCE INITIATION OF ALLIANCE OPERATIONS IN GERMANY
STERLING WINTHROP AND BIOMIRA SIGN AGREEMENTS FOR THE DEVELOPMENT OF ANTIBODY-BASED CANCER PRODUCTS
BIOMIRA AND STERLING WINTHROP SIGN AGREEMENTS FOR THE DEVELOPMENT OF ANTIBODY-BASED CANCER PRODUCTS
NEORX TO GRANT LICENSE FOR RHENIUM CANCER THERAPY TO STERLING WINTHROP AS PART OF A $10 MILLION AGREEMENT
SANOFI WINTHROP AND RHONE-POULENC RORER INC. SIGN MARKETING, DISTRIBUTION AGREEMENT FOR ANTI-ANGINAL
STERLING WINTHROP AND ELF SANOFI ANNOUNCE JOINT OPERATIONS NOW UNDER WAY THROUGHOUT EUROPE WITH ADDITION OF SCANDINAVIAN COUNTRIES
STERLING WINTHROP'S PHARMACEUTICALS UNIT, SANOFI WINTHROP, LAUNCHES PRIMACOR I.V. IN THE U.S.
STERLING WINTHROP'S U.S. PHARMACEUTICALS UNIT, SANOFI WINTHROP PHARMACEUTICALS, AND MEDRAD, ANNOUNCE DEVELOPMENT AGREEMENT
STERLING WINTHROP INC. AND ADVANCED MAGNETICS, INC. ANNOUNCE MRI CONTRAST AGENT LICENSE AND MARKETING AGREEMENT
Unilife signs exclusive agreement with Sanofi-Aventis.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters